{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:36:25Z","timestamp":1769837785710,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["99002224"],"award-info":[{"award-number":["99002224"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cellimm.2023.104787","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:25:06Z","timestamp":1699701906000},"page":"104787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Anti-CD19\/CD8 bispecific T cell engager for the potential treatment of B cell malignancies"],"prefix":"10.1016","volume":"393-394","author":[{"given":"Nafiseh","family":"Maghsoodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadrasul","family":"Zareinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Golestan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Mahmoudi Maymand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-8722","authenticated-orcid":false,"given":"Amin","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cellimm.2023.104787_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cellimm.2023.104787_b0010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00247-019-04529-8","article-title":"Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"49","author":"McCarten","year":"2019","journal-title":"Pediatr. Radiol."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-11840-3","article-title":"Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019","volume":"21","author":"Touma","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cellimm.2023.104787_b0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2012.151","article-title":"A record-based case\u2013control study of natural background radiation and the incidence of childhood leukaemia and other cancers in Great Britain during 1980\u20132006","volume":"27","author":"Kendall","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cellimm.2023.104787_b0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2023.104787_b0040","series-title":"Mabs","article-title":"The making of bispecific antibodies","author":"Brinkmann","year":"2017"},{"issue":"5795","key":"10.1016\/j.cellimm.2023.104787_b0045","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cellimm.2023.104787_b0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12245","article-title":"Novel immunotherapies for hematologic malignancies","volume":"263","author":"Nelson","year":"2015","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0060","first-page":"2098","article-title":"A recombinant bispecific single-chain antibody, CD19\u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.cellimm.2023.104787_b0065","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cellimm.2023.104787_b0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2013.01.002","article-title":"Retargeting of regulatory T cells to surface-inducible autoantigen La\/SS-B","volume":"42","author":"Koristka","year":"2013","journal-title":"J. Autoimmun."},{"issue":"7873","key":"10.1016\/j.cellimm.2023.104787_b0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cellimm.2023.104787_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2020.06.006","article-title":"Performance and its limits in rigid body protein-protein docking","volume":"28","author":"Desta","year":"2020","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.cellimm.2023.104787_b0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/prot.25219","article-title":"New additions to the C lus P ro server motivated by CAPRI","volume":"85","author":"Vajda","year":"2017","journal-title":"Proteins Struct. Funct. Bioinf."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/mab.2017.0049","article-title":"Using a dihydrofolate reductase-based strategy for producing the biosimilar version of pertuzumab in CHO-S cells","volume":"37","author":"Ramezani","year":"2018","journal-title":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy"},{"key":"10.1016\/j.cellimm.2023.104787_b0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pep.2017.04.013","article-title":"Improving Pertuzumab production by gene optimization and proper signal peptide selection","volume":"135","author":"Ramezani","year":"2017","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.cellimm.2023.104787_b0100","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0110","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellimm.2023.104787_b0120","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1182\/blood-2019-129652","article-title":"Bispecific T-cell engager (BiTE) antibody based immunotherapy for treatment of relapsed refractory multiple myeloma (RRMM): A systematic review of preclinical and clinical trials","volume":"134","author":"Shah","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2023.104787_b0125","doi-asserted-by":"crossref","unstructured":"Frey, N.V. and D.L. Porter, Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology 2014, the American Society of Hematology Education Program Book, 2016. 2016(1): p. 567-572.","DOI":"10.1182\/asheducation-2016.1.567"},{"issue":"26","key":"10.1016\/j.cellimm.2023.104787_b0130","first-page":"5154","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"4","key":"10.1016\/j.cellimm.2023.104787_b0135","doi-asserted-by":"crossref","first-page":"e95517","DOI":"10.1371\/journal.pone.0095517","article-title":"Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8","volume":"9","author":"Michalk","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0140","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.cellimm.2023.104787_b0145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0150","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/cancers14061436","article-title":"Emerging canonical and non-canonical roles of granzyme B in health and disease","volume":"14","author":"Tibbs","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.cellimm.2023.104787_b0155","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2004-03-0859","article-title":"Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells","volume":"104","author":"Grossman","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cellimm.2023.104787_b0160","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","article-title":"Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells","volume":"189","author":"Feldmann","year":"2012","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cellimm.2023.104787_b0165","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni969","article-title":"Similarities and differences in CD4+ and CD8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2023.104787_b0170","first-page":"405","article-title":"CD40L expression permits CD8+ T cells to execute immunologic helper functions","volume":"122","author":"Frentsch","year":"2013","journal-title":"Blood, J. Am. Soc. Hematol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874923001260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874923001260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T23:15:53Z","timestamp":1757805353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874923001260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":34,"alternative-id":["S0008874923001260"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104787","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD19\/CD8 bispecific T cell engager for the potential treatment of B cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2023.104787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104787"}}